BioAge

Approach

Thermal partnered to establish the narrative infrastructure that let each milestone land with maximum impact.

• • Translated BioAge’s scientific identity to key audiences: Established the company’s core positioning as a data-first, human-centric aging research organization using real longitudinal biobank data, distinguishing it from longevity companies making claims ahead of clinical evidence.
  • Developed Kristen Fortney as a tier-one executive voice: Executed an ongoing CEO profiling strategy targeting mainstream and trade media, reinforcing Fortney’s position as a defining scientific voice in aging therapeutics.
  • Designed and executed funding and IPO announcement strategies: Built coordinated media campaigns around BioAge’s financing milestones, sequencing embargoes and outreach to maximize coverage across business and trade outlets.
  • Managed media strategy around BioAge’s lead drug candidate: Coordinated embargoes with priority reporters at key trade outlets across multiple Phase 1 readouts for BGE-102, BioAge’s oral anti-inflammatory pill, building the reporter relationships that made BioAge a standing source on the NLRP3 beat.
  • Framed BioAge within the emerging NLRP3 category: As major pharma companies entered the space, proactively contextualized BioAge’s data against competitors and the broader market opportunity, pitching the company as the clinical-stage frontrunner in a class attracting billion-dollar bets.

Impact

Through our partnership, BioAge has:

• • Landed a TIME magazine CEO profile: Secured a feature on Kristen Fortney in TIME, reaching a mainstream audience with BioAge’s story at a key moment
  • Drove timely press around clinical and funding milestones: Coverage of BioAge’s clinical trial progress and funding rounds ran in key tier 1 and trade publications, including Bloomberg, Endpoints, STAT News, and Fierce.
  • Secured mainstream longevity coverage: BioAge’s approach earned dedicated features in Tier 1 publications including CNBC, TIME, and Sky News, and mentions in the Wall Street Journal and Freakonomics.
  • Made BioAge part of the NLRP3 category conversation: Thermal’s context-building secured BioAge inclusion in broader category stories as the Lilly/Ventyx deal elevated the class, with the company cited as a clinical-stage comparator in Endpoints News’ coverage of the $1.2 billion acquisition.